natgillin/translations-raw huggingface dataset:
Adverse reactions seen in all clinical studies are listed below according to MedDRA system organ class and in decreasing frequency which is defined as follows: Very Common ( &gt; 1/10); Common ( &gt; 1/100 to &lt; 1/10); Uncommon ( &gt; 1/1000 to &lt; 1/100).
Nuspojave opažene u svim kliničkim ispitivanjima navedene su niže prema klasifikaciji organskih sustava MedDRA te redoslijedom prema sve manjoj učestalosti definiranoj kao: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100).
Adverse reactions that may suggest increase in prolactin levels (e.g. amenorrhoea, galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in &lt; 1% of subjects.
Nuspojave koje mogu ukazivati na porast razine prolaktina (npr. amenoreja, galaktoreja, poremećaj menstruacije i ginekomastija) ukupno su zabilježene u &lt; 1% ispitanika.
Adverse reactions were categorized as very common (( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) or not known (cannot be estimated from available data).
Nuspojave su kategorizirane kao vrlo često (( 1/10), često ( 1/100 to &lt; 1/10), manje često ( 1/1000 to &lt; 1/100), rijetko ( 1/10000 to &lt; 1/1000), vrlo rijetko ( &lt; 1/10000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions which occurred in &gt; 1 % of Revatio-treated patients and were more frequent ( &gt; 1 % difference) on Revatio in the pivotal study or in the Revatio combined data set of both the placebo-controlled studies in pulmonary arterial hypertension, at doses of 20, 40 or 80 mg TID are listed in the table below by class and frequency grouping (very common ( 1/10), common ( 1/100 to
U sljedećoj su tablici navedene nuspojave koje su nastupile u &gt; 1% bolesnika liječenih lijekom Revatio i koje su se javile češće (razlika &gt; 1%) uz primjenu lijeka Revatio u dozama od 20, 40 ili 80 mg TID u pivotalnom ispitivanju ili u kombiniranim podacima iz oba placebom kontrolirana ispitivanja u plućnoj arterijskoj hipertenziji.
Adverse reactions which occurred in &gt; 1 % of Revatio-treated patients and were more frequent ( &gt; 1 % difference) on Revatio in the pivotal study or in the Revatio combined data set of both the placebo-controlled studies in pulmonary arterial hypertension,, at doses of 20, 40 or 80 mg TID are listed in the table below by class and frequency grouping (very common ( 1/10), common ( 1/100 to
U sljedećoj su tablici navedene nuspojave koje su nastupile u &gt; 1% bolesnika liječenih lijekom Revatio i koje su se javile češće (razlika &gt; 1%) uz primjenu lijeka Revatio u dozama od 20, 40 ili 80 mg TID u pivotalnom ispitivanju ili u kombiniranim podacima iz oba placebom kontrolirana ispitivanja u plućnoj arterijskoj hipertenziji.
Adverse reactions with asfotase alfa are listed by system organ class and preferred term using MedDRA frequency convention very common (1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Nuspojave opažene za asfotazu alfa navedene su prema klasifikaciji organskih sustava i preporučenom izrazu na temelju MedDRA-inog prikaza učestalosti nuspojava kao vrlo često (1/10), često (1/100 i &lt; 1/10), manje često (1/1000 i &lt; 1/100), rijetko (1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions, considered at least possibly attributable to cinacalcet treatment in the placebo controlled studies and single-arm studies based on best-evidence assessment of causality are listed below using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Nuspojave, za koje se smatra da postoji barem mogućnost da se mogu pripisati liječenju sinakalcetom u placebom kontroliranim ispitivanjima i ispitivanjima na jednoj skupini prema procjeni uzročno- posljedične veze na temelju najboljih dokaza navedene su niže prema sljedećoj konvenciji: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in ≥ 1/10 and in ≥ 1/100 to &lt; 1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.
Nuspojave, vjerojatno ili moguće povezane s mofetilmikofenolatom, prijavljene u kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci za dozu od 2 g), srcem ili jetrom kod ≥ 1/10 i ≥ 1/100 do &lt; 1/10 bolesnika liječenih mofetilmikofenolatom, navedene su u sljedećoj tablici.
Adverse reactionsare listed below using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Nuspojave su navedene niže i prema učestalosti razvrstane su na sljedeći način: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
Advocate for extra-large dogs ( &gt; 25–40 kg)
Advocate za vrlo velike pse ( &gt; 25–40 kg)
Advocate for extra-large dogs ( &gt; 25–40 kg)
Advocate za vrlo velike pse ( &gt; 25-40 kg)
Advocate for large cats ( &gt; 4–8 kg)
Advocate za velike mačke ( &gt; 4–8 kg)
Advocate for large cats ( &gt; 4–8 kg)
Advocate za velike mačke ( &gt; 4-8 kg)
Advocate for large dogs ( &gt; 10–25 kg)
Advocate za velike pse ( &gt; 10–25 kg)
Advocate for large dogs ( &gt; 10–25 kg)
Advocate zavelike pse ( &gt; 10-25 kg)
Advocate for medium dogs ( &gt; 4–10 kg)
Advocate za srednje velike pse ( &gt; 4 -10 kg)
Advocate for medium dogs ( &gt; 4–10 kg)
Advocate za srednje velike pse ( &gt; 4–10 kg)
Aerivio Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 &lt; 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Aerivio Spiromax je indiciran za simptomatsko liječenje bolesnika s KOPB-om, s FEV1 &lt; 60% predviđene normale (prije primjene bronhodilatatora) i s ponavljajućim egzacerbacijama u anamnezi, koji imaju značajne simptome unatoč redovitoj terapiji bronhodilatatorom.
Aerivio Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 &lt; 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Airexar Spiromax je indiciran za simptomatsko liječenje bolesnika s KOPB-om, s FEV1 &lt; 60% predviđene normale (prije primjene bronhodilatatora) i s ponavljajućim egzacerbacijama u anamnezi, koji imaju značajne simptome unatoč redovitoj terapiji bronhodilatatorom.
Aflibercept administration should be suspended for ≥2 grams of proteinuria/24 hours and restarted when proteinuria is &lt; 2 grams/24 hours.
Primjenu aflibercepta treba prekinuti kada je proteinurija u 24 sata ≥ 2 grama i ponovno uvesti kada proteinurija u 24 sata bude &lt; 2 grama.
AFP* &lt; 20 ng/mL, platelets ≥ 90 x 109/L, AND albumin ≥ 35 g/L prior to treatment
AFP* &lt; 20 ng/ml, broj trombocita ≥ 90 x 109/l i albumin ≥ 35 g/l prije početka liječenja
After 12 months, these patients showed a difference of 28% between treatment groups (67% for Visudyne patients compared to 39% for placebo patients, p &lt; 0.001); the benefit was maintained at 24 months (59% versus 31%, p &lt; 0.001).
Nakon 12 mjeseci, u tih je bolesnika razlika između dviju ispitivanih skupina iznosila 28% (67% bolesnika koji su primali Visudyne, u usporedbi s 39% onih koji su primali placebo, p &lt; 0,001); ta se razlika održala i nakon 24 mjeseca (59% u odnosu na 31%, p &lt; 0,001).
After 16 weeks’ treatment, there were significant improvements from baseline in exercise capacity: the mean increase in 6- minute walk distance was 91.4 metres from 332.6 metres on average at baseline (p &lt; 0.001).
Nakon 16 tjedana liječenja došlo je do znatnog poboljšanja fizičke sposobnosti u odnosu na početnu vrijednost: srednje povećanje tijekom 6-minutne postignute udaljenosti hodom bilo je 91,4 metra u odnosu na 332,6 metara koja čine prosječnu prijeđenu udaljenost prije liječenja (p &lt; 0,001).
After 16 weeks’ treatment, there were significant improvements from baseline in exercise capacity: the mean increase in 6- minute walk distance was 91.4 metres from 332.6 metres on average at baseline (p &lt; 0.001).
Nakon 16 tjedana liječenja došlo je do znatnog poboljšanja fizičke sposobnosti u odnosu na početnu vrijednost: srednje povećanje tijekom 6-minutne postignute udaljenosti hodomg bilo je 91,4 metra u odnosu na 332,6 metara koja čine prosječnu prijeđenu udaljenost prije liječenja (p &lt; 0,001).
After 19 months (median) treatment, bone mineral density (BMD) had increased in the lumbar spine and total hip, respectively, by 9 % and 4 % compared with placebo (p &lt; 0.001).
Nakon 19 mjeseci (medijan) liječenja mineralna gustoća kosti (BMD) u lumbalnom dijelu kralježnice povećala se za 9%, a na cijelom kuku za 4% (p &lt; 0,001) u odnosu na placebo.
After 24 weeks of treatment, the primary endpoint of mean change from baseline in HbA1c was -1.83% in the combination group versus -0.96% in the pioglitazone group (p &lt; 0.0001) and -0.99% in the metformin group (p &lt; 0.0001).
Nakon 24 tjedna liječenja, primarni ishod bila je prosječna promjena u odnosu na početnu vrijednost HbA1c i iznosila je -1,83% u skupini koja je primala kombinaciju nasuprot -0,96% u skupini koja je primala pioglitazon (p &lt; 0,0001) i -0,99% u skupini koja je primala metformin (p &lt; 0,0001).
After 24 weeks of treatment, the primary endpoint of mean change from baseline in HbA1c was -1.83% in the combination group versus -0.96% in the pioglitazone group (p &lt; 0.0001) and -0.99% in the metformin group (p &lt; 0.0001).
Nakon 24 tjedna liječenja, primarni ishod bila je srednja vrijednost promjene u odnosu na početnu vrijednost HbA1c i iznosila je -1,83% u skupini koja je primala kombinaciju nasuprot -0,96% u skupini koja je primala pioglitazon (p &lt; 0,0001) i -0,99% u skupini koja je primala metformin (p &lt; 0,0001).
After 240 weeks of treatment, 117 of 141 subjects (83%) randomised to tenofovir disoproxil fumarate had HBV DNA &lt; 400 copies/ml, and 51 of 79 subjects (65%) had ALT normalisation.
Nakon 240 tjedana liječenja, 117 od 141 (83%) ispitanika randomiziranogih za tenofovirdizoproksilfumarat imalo je HBV DNK &lt; 400 kopija/ml, a 51 od 79 (65%) ispitanika imalo je normalizaciju ALT-a.
After 48 weeks of treatment with lopinavir/ritonavir, efavirenz and nucleoside reverse transcriptase inhibitors, plasma HIV RNA ≤ 400 copies/ml was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with &lt; 10-fold, 10 to 40-fold, and &gt; 40-fold reduced susceptibility to lopinavir at baseline, respectively.
Nakon 48 tjedana terapije lopinavirom/ritonavirom, efavirenzom i nukleozidnim inhibitorima reverzne transkriptaze, ≤ 400 kopija HIV RNA/ml plazme nađeno je, redom, u 93% (25/27), 73% (11/15), i 25% (2/8) bolesnika s &lt; 10 puta manjom, 10-40 puta manjom, i &gt; 40 puta manjom početnom osjetljivošću na lopinavir.
After 5 years of treatment, the endometrial thickness in the bazedoxifene 20 mg group did not change and remained similar to placebo; there were no cases of endometrial cancer in the bazedoxifene 20 mg group compared to 6 cases in the placebo group (p &lt; 0.05).
Nakon 5 godina liječenja, debljina endometrija u skupini liječenoj bazedoksifenom, u dozi od 20 mg, nije se promijenila i ostala je slična kao kod primjene placeba; u skupini koja je primala bazedoksifen 20 mg nije zabilježen niti jedan slučaj raka endometrija, dok ih je u skupini koja je primala placebo bilo šest (p &lt; 0,05).
After 6 months, Aclasta showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p &lt; 0.001).
Nakon 6 mjeseci, Aclasta je pokazala 96% (169/176) i 89% (156/176) odgovor i stope normalizacije razina alkalne fosfataze u serumu (SAP) u usporedbi s 74% (127/171) i 58% (99/171) za risedronat (za sve p &lt; 0,001).
After 6 months, zoledronic acid showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p &lt; 0.001).
Nakon 6 mjeseci pri primjeni zoledronatne kiseline zabilježen je odgovor od 96% (169/176) te normalizacija razina alkalne fosfataze u serumu od 89% (156/176) u usporedbi sa 74% (127/171), odnosno 58% (99/171) pri primjeni risedronata (sve p &lt; 0,001).
After 6 months, zoledronic acid showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p &lt; 0.001).
Nakon 6 mjeseci, zoledronatna kiselina je pokazala 96% (169/176) i 89% (156/176) odgovor i normalizaciju razina alkalne fosfataze u serumu naspram 74% (127/171) i 58% (99/171) za risedronat (sve p &lt; 0,001).
After 7 years of treatment, the endometrial thickness in the bazedoxifene 20 mg group did not change and remained similar to placebo; there were no cases of endometrial cancer in the bazedoxifene 20 mg group compared to 7 cases in the placebo group (p &lt; 0.008).
Nakon 7 godina liječenja, debljina endometrija u skupini liječenoj bazedoksifenom, u dozi od 20 mg, nije se promijenila i ostala je slična kao kod primjene placeba; u skupini koja je primala bazedoksifen 20 mg nije zabilježen niti jedan slučaj raka endometrija, dok ih je u skupini koja je primala placebo bilo sedam (p &lt; 0,008).
After a median follow-up of 32 weeks, the tritherapy with the three nucleosides ZDV/3TC/ABC was shown to be virologically inferior to the two other arms regardless of baseline viral load ( &lt; or &gt; 100 000 copies/ml) with 26 % of subjects on the ZDV/3TC/ABC arm, 16 % on the ZDV/3TC/EFV arm and 13 % on the 4 drug arm categorised as having virological failure (HIV RNA &gt; 200 copies/ml).
Nakon razdoblja praćenja s medijanom od 32 tjedna, trojna terapija s tri nukleozida ZDV/3TC/ABC pokazala se virološki inferiornom u odnosu na ostale dvije skupine, neovisno o inicijalnom virusnom opterećenju ( &lt; ili &gt; 100 000 kopija/ml) s 26% ispitanika u terapijskoj skupini ZDV/3TC/ABC, 16% u terapijskoj skupini ZDV/3TC/EFV i 13% u skupini koja je primala 4 lijeka koji su kategorizirani je kao virološki neuspjeh (HIV RNA &gt; 200 kopija/ml).
After a single 250 mg dose in subjects with severe renal impairment (CLcr &lt; 30 mL/min) not requiring peritoneal dialysis or haemodialysis, crizotinib AUC and Cmax increased by 79% and 34%, respectively, compared to those with normal renal function.
Nakon pojedinačne doze od 250 mg u bolesnika sa teškim oštećenjem bubrega (CLcr &lt; 30 mL/min) koje ne zahtjeva peritonealnu dijalizu ili hemodijalizu, AUC i Cmax je očekivano povećana 79% i 34%, u usporedbi sa bolesnicima normalne bubrežne funkcije.
After a single 400 mg oral dose of [14C]-sofosbuvir, sofosbuvir and GS-331007 accounted for approximately 4% and &gt; 90% of drug-related material (sum of molecular weight-adjusted AUC of sofosbuvir and its metabolites) systemic exposure, respectively.
Nakon jedne peroralne doze od 400 mg [14C]-sofosbuvira, sofosbuvir i GS-331007 činili su približno 4% odnosno &gt; 90% sistemske izloženosti tvarima povezanima s lijekom (zbroj molekularnoj težini prilagođenog AUC sofosbuvira i njegovih metabolita).
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10 % of peak after 4 hours and &lt; 1 % of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1 % of peak prior to the second infusion of zoledronic acid on day 28.
Nakon početka infuzije zoledronatne kiseline, koncentracija zoledronatne kiseline u plazmi brzo se povisila i postigla vršnu vrijednost na kraju razdoblja infuzije, nakon čega je uslijedilo brzo sniženje na &lt; 10% vršne vrijednosti nakon 4 sata te &lt; 1% vršne vrijednosti nakon 24 sata, a potom produljeno razdoblje vrlo niskih koncentracija koje nisu prelazile 0,1% vršne vrijednosti prije druge infuzije zoledronatne kiseline 28. dana.
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.
Nakon početka infuzije zoledronatne kiseline, koncentracija zoledronatne kiseline u plazmi brzo se povisila i postigla vršnu vrijednost na kraju razdoblja infuzije, nakon čega je uslijedilo brzo sniženje na &lt; 10% vršne vrijednosti nakon 4 sata te &lt; 1% vršne vrijednosti nakon 24 sata, a potom produljeno razdoblje vrlo niskih koncentracija koje nisu prelazile 0,1% vršne vrijednosti prije druge infuzije zoledronatne kiseline 28. dana.
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.
Nakon početka infuzije zoledronatne kiseline, koncentracija zoledronatne kiseline u plazmi brzo se povisila i postigla vršnu vrijednost na kraju razdoblja infuzije, nakon čega je uslijedilo brzo sniženje na &lt; 10% vršne vrijednosti nakon 4 sata te &lt; 1% vršne vrijednosti nakon 24 sata, s narednim produljenim razdobljem vrlo niskih koncentracija koje nisu prelazile 0,1% vršne vrijednosti prije druge infuzije zoledronatne kiseline 28. dana.
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.
Nakon početka infuzije zoledronatne kiseline, koncentracija zoledronatne kiseline u plazmi brzo se povisila i postigla vršnu vrijednost na kraju razdoblja infuzije, nakon čega je uslijedilo brzo sniženje na &lt; 10% vršne vrijednosti nakon 4 sata te &lt; 1% vršne vrijednosti nakon 24 sata,s narednim produljenim razdobljem vrlo niskih koncentracija koje nisu prelazile 0,1% vršne vrijednosti prije druge infuzije zoledronatne kiseline 28. dana.
After initiation of the zoledronic acid infusion, plasma concentrations of the active substance increased rapidly, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak levels.
Nakon početka primjene infuzije zoledronatne kiseline, koncentracija zoledronatne kiseline u plazmi naglo se povećala, dosegnuvši vršnu koncentraciju na kraju infuzije, nakon čega je uslijedio brzi pad do &lt; 10% od vršne koncentracije nakon 4 sata te &lt; 1% od vršne koncentracije nakon 24 sata, s posljedičnim produženim razdobljem vrlo niskih koncentracija koje nisu prelazile 0,1% vršne koncentracije.
After initiation of the zoledronic acid infusion, plasma concentrations of the active substance increased rapidly, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak levels.
Nakon uvođenja infuzije zoledronatne kiseline, koncentracije djelatne tvari u plazmi brzo su se povećavale, pri ćemu su vršnu vrijednost postigle na kraju perioda infuzije, nakon čega je slijedio brzi pad na &lt; 10% vršne vrijednosti nakon 4 sata, zatim na &lt; 1% vršne vrijednosti nakon 24 sata, s produljenim periodom vrlo niskih koncentracija koje nisu prelazile 0,1% vršnih razina.
After primary vaccination the rate of subjects with neutralising antibody titres &gt; 20, seroconversion rate and seroconversion factor as measured by microneutralisation assay (MN) in adults aged 18 to 59 years and in older people aged 60 years and above were as follows:
Nakon prvog cijepljenja, stopa ispitanika s neutralizirajućim titrima protutijela &gt; 20, stopa serokonverzije i faktor serokonverzije, određeni testom mikroneutralizacije (MN) u ispitanika od 18 do 59 godina i starijih osoba od 60 i više godina, bili su sljedeći:
After the first injection, a moderate and transient local reaction ( &lt; 2 cm) is commonly observed.
Nakon prve primjene često su primijećene lokalne (≤ 2 cm) i prolazne reakcije.
After the first injection, a moderate and transient local reaction ( &lt; 2 cm) is commonly observed.
Poslije prve primjene često su primijećene lokalne (≤ 2 cm) prolazne reakcije.
After the platelet count has fallen to &lt; 150 x 109/l, resume dosing with once weekly dose reduced by 1 μg/kg
Nakon što je broj trombocita pao na &lt; 150 x 109/l, ponovno početi davati lijek jednom tjedno u dozi umanjenoj za 1 µg/kg
After three weeks of treatment, the improvement in inspiratory capacity with Ultibro Breezhaler was greater (320 ml, p &lt; 0.001) and exercise endurance time increased (59.5 seconds, p=0.006) compared to placebo.
Nakon tri tjedna liječenja, poboljšanje inspiratornog kapaciteta s Ultibro Breezhalerom bilo je veće (320 ml, p &lt; 0,001), a vrijeme izdržavanja napora povećalo se (59,5 sekundi, p=0,006) u usporedbi s placebom.
After three weeks of treatment, the improvement in inspiratory capacity with Ulunar Breezhaler was greater (320 ml, p &lt; 0.001) and exercise endurance time increased (59.5 seconds, p=0.006) compared to placebo.
Nakon tri tjedna liječenja, poboljšanje inspiratornog kapaciteta s Ulunar Breezhalerom bilo je veće (320 ml, p &lt; 0,001), a vrijeme izdržavanja napora povećalo se (59,5 sekundi, p=0,006) u usporedbi s placebom.
After three weeks of treatment, the improvement in inspiratory capacity with Xoterna Breezhaler was greater (320 ml, p &lt; 0.001) and exercise endurance time increased (59.5 seconds, p=0.006) compared to placebo.
Nakon tri tjedna liječenja, poboljšanje inspiratornog kapaciteta s Xoterna Breezhalerom bilo je veće (320 ml, p &lt; 0,001), a vrijeme izdržavanja napora povećalo se (59,5 sekundi, p=0,006) u usporedbi s placebom.
Age &gt; 75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment.
Dob &gt; 75 godina i vaskularna demencija/miješani tip demencije identificirani su kao čimbenici rizika za cerebrovaskularne događaje povezane s primjenom olanzapina.
Age &gt; 75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment.
Dob iznad 75 godina i demencija vaskularnog/miješanog tipa bili su prepoznati kao čimbenici rizika za CV štetne događaje povezane s liječenjem olanzapinom.
Age &gt; 75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment.
Dob starija od 75 godina i demencija vaskularnog/miješanog tipa bili su prepoznati kao čimbenici rizika za CV štetne događaje povezane s liječenjem olanzapinom.